DONGFENG GROUP
00489
CHINA SHENHUA
01088
CHINA COAL
01898
PETROCHINA
00857
CHINAHONGQIAO
01378
HK Stock MarketDetailed Quotes
02563 BIOSTAR PHARM-B
- 29.200
- -0.050-0.17%
Market Closed Dec 4 16:08 CST
10.65BMarket Cap-59109P/E (TTM)
29.850High28.900Low371.60KVolume29.250Open29.250Pre Close10.86MTurnover0.17%Turnover RatioLossP/E (Static)364.59MShares30.50052wk High14.43P/B6.33BFloat Cap19.48052wk Low--Dividend TTM216.72MShs Float30.500Historical High--Dividend LFY3.25%Amplitude19.480Historical Low29.213Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
About BIOSTAR PHARM-B Company
Huahao Zhongtian is a national high-tech enterprise founded by a team of scientists studying in the US. Relying on advanced core technology platforms such as composite biosynthesis, it focuses on developing new anti-cancer drugs with independent intellectual property rights. After nearly 20 years of development, the company has become an integrated biomedical company integrating R&D, production and commercialization of new drugs. The company is an innovative pharmaceutical company focusing on the field of oncology treatment.
Company Profile
Symbol02563
Company NameBIOSTAR PHARM-B
ISINCNE100006NB3
Listing DateOct 31, 2024
Issue Price16.00
Shares Offered14.59M share(s)
FoundedJul 11, 2002
Registered AddressChina
ChairmanTang Li
Secretaryyibinliukailin chen
Audit InstitutionKPMG
Company CategoryOther
Registered OfficeRoom 310, 3rd Floor, Building 3, No. 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing, China
Head Office and Principal Place of BusinessRoom 02, 8th floor, Tung Tzu Commercial Centre, 246 Des Voeux Road West, Hong Kong
Fiscal Year Ends12-31
Employees230
MarketHong Kong motherboard
Phone(86)1067864938
Emailcontact@biostar-pharma.com
BusinessThe company is an innovative pharmaceutical company focusing on the field of oncology treatment. Adhering to the development concept of “committed to original innovative drugs to benefit cancer patients”, the company relies on a key technology platform for new drug development to continuously develop innovative anti-tumor drugs with high clinical value, wide market space, and high technical barriers to provide safe, effective and economical treatment options for patients around the world.
Company Executives
- Name
- Position
- Salary
- Tang Li
- Chairman, Executive Director, Chief Marketing Officer, Chief Scientific Officer, Chairman of the Strategy Committee, Nomination Committee Members, Co-founder, Authorized Representative
- --
- Qiu Rongguo
- Vice Chairman, CEOs, Executive Director, General Manager, Member of the Remuneration and Assessment Committee, Strategy Committee Members, Co-founder
- --
- cheng zhang
- Executive Director, Deputy General Manager
- --
- jin guan
- Executive Director, Deputy General Manager, Strategy Committee Members
- --
- jin tang
- Non-executive Directors
- --
- pai zhu
- Non-executive Directors
- --
- songdong meng
- Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members, Member of the Remuneration and Assessment Committee
- --
- jingyao qi
- Independent Non-Executive Director, Chairman of the Remuneration and Assessment Committee, Audit Committee Members
- --
- dong ran
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- --
- shufeng zhang
- Chairman of the Supervisory Board
- --
- quan zhou
- Financial Manager, Auditors
- --
- rixiang kong
- Director of R&D, Employee representative supervisor
- --
- kailin liu
- Investment Director, Joint Company Secretary, Board Secretary
- --
- fei peng
- Chief Financial Officer
- --
- yibin chen
- Joint Company Secretary, Authorized Representative
- --
